Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GALECTIN THERAPEUTICS INCGALT · Entity 5577 | Director · 10% owner | July 31, 2026 | August 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GALECTIN THERAPEUTICS INC
Report date July 31, 2026 · Filed August 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectRichard E. Uihlein Stock Trust | 42,162,911 |
Reported balance
After 2026-07-31 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-07-31 · Exercise / conversion · Acquired 31,825,235 · Balance 42,162,911 |
| Common StockSEC Table I · non-derivative | IndirectRichard E. Uihlein Stock Trust | 44,713,843 |
Reported balance
After 2026-07-31 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-07-31 · Exercise / conversion · Acquired 2,550,932 · Balance 44,713,843 |
| Line of Credit Convertible NotesSEC Table II · derivative / convertible security · Conversion / exercise price $3.00 · Expires 2027-06-30 | IndirectRichard E. Uihlein Stock Trust | 0 |
Reported balance
After 2026-07-31 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-07-31 · Exercise / conversion · Disposed Not disclosed · Balance 0 F1: Consists of $91,000,000 in principal and $14,475,705 in accrued interest. F3: The Line of Credit Convertible Notes are exercisable upon issuance when the issuer draws on the Line of Credit. Notes were issued on December 19, 2022; March 31, 2023; June 30, 2023; December 29, 2023; March 29, 2024; June 28, 2024; September30, 2024; April 30, 2025; June 30, 2025 and December 31, 2025. There was no expiration date; however, the maturity date of all Line of Credit Convertible Notes was June 30, 2027. |
| Line of Credit Convertible NotesSEC Table II · derivative / convertible security · Conversion / exercise price $4.05 · Expires 2027-06-30 | IndirectRichard E. Uihlein Stock Trust | 0 |
Reported balance
After 2026-07-31 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-07-31 · Exercise / conversion · Disposed Not disclosed · Balance 0 F2: Consists of $10,000,000 of principal and $331,275 of accrued interest. F3: The Line of Credit Convertible Notes are exercisable upon issuance when the issuer draws on the Line of Credit. Notes were issued on December 19, 2022; March 31, 2023; June 30, 2023; December 29, 2023; March 29, 2024; June 28, 2024; September30, 2024; April 30, 2025; June 30, 2025 and December 31, 2025. There was no expiration date; however, the maturity date of all Line of Credit Convertible Notes was June 30, 2027. |
| Common StockSEC Table I · non-derivative | IndirectBy Ed Uihlein Family Foundation | 27,710 |
Reported balance
Holding disclosure · report date 2026-07-31 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 27,710 F4: The reporting person is president and director of Ed Uihlein Family Foundation, a not-for-profit corporation. The reporting person has no pecuniary interest in the shares, however, he shares voting and dispositive power over the shares and, therefore, remains the beneficial owner of the shares solely for the purposes of Section 13(d) of the Securities Exchange Act of 1934. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of $91,000,000 in principal and $14,475,705 in accrued interest.
F2: Consists of $10,000,000 of principal and $331,275 of accrued interest.
F3: The Line of Credit Convertible Notes are exercisable upon issuance when the issuer draws on the Line of Credit. Notes were issued on December 19, 2022; March 31, 2023; June 30, 2023; December 29, 2023; March 29, 2024; June 28, 2024; September30, 2024; April 30, 2025; June 30, 2025 and December 31, 2025. There was no expiration date; however, the maturity date of all Line of Credit Convertible Notes was June 30, 2027.
F4: The reporting person is president and director of Ed Uihlein Family Foundation, a not-for-profit corporation. The reporting person has no pecuniary interest in the shares, however, he shares voting and dispositive power over the shares and, therefore, remains the beneficial owner of the shares solely for the purposes of Section 13(d) of the Securities Exchange Act of 1934.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 29, 2019 Filed Jan 30, 2019 22:31 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseCommon Stock | 48,500 | $4.87 | $236,243.50 |
DisclosureSEC source: 0001179022-19-000021 · edgar.xml · nonDerivative · entry 2 Uihlein Richard E · CIK 0001694903 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,586,789 F2 · price: The shares were sold in multiple transactions at prices ranging from $4.75 to $5.00. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| January 29, 2019 Filed Jan 31, 2019 15:55 UTC Amendment | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseCommon Stock | 48,500 | $4.87 | $236,243.50 |
DisclosureSEC source: 0001179022-19-000023 · edgar.xml · nonDerivative · entry 2 Uihlein Richard E · CIK 0001694903 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,586,789 F2 · price: The shares were purchased in multiple transactions at prices ranging from $4.75 to $5.00. This amount represents the weighted average purchase price of such transactions. The reporting person undertakes to provide full information regarding the number of shares purchased at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. F3 · price: This Form 4 is being amended to correct footnotes (1) and (2) for the purchase transactions on January 28, 2019 and January 29, 2019, which footnotes incorrectly stated that the shares were sold in multiple transactions, but should have stated that the shares were purchased in multiple transactions. Read SEC document |
| January 28, 2019 Filed Jan 30, 2019 22:31 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseCommon Stock | 3,000 | $4.77 | $14,315.10 |
DisclosureSEC source: 0001179022-19-000021 · edgar.xml · nonDerivative · entry 1 Uihlein Richard E · CIK 0001694903 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,538,289 F1 · price: The shares were sold in multiple transactions at prices ranging from $4.77 to $4.78. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| January 28, 2019 Filed Jan 31, 2019 15:55 UTC Amendment | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseCommon Stock | 3,000 | $4.77 | $14,315.10 |
DisclosureSEC source: 0001179022-19-000023 · edgar.xml · nonDerivative · entry 1 Uihlein Richard E · CIK 0001694903 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,538,289 F1 · price: The shares were purchased in multiple transactions at prices ranging from $4.77 to $4.78. This amount represents the weighted average purchase price of such transactions. The reporting person undertakes to provide full information regarding the number of shares purchased at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. F3 · price: This Form 4 is being amended to correct footnotes (1) and (2) for the purchase transactions on January 28, 2019 and January 29, 2019, which footnotes incorrectly stated that the shares were sold in multiple transactions, but should have stated that the shares were purchased in multiple transactions. Read SEC document |
| January 16, 2019 Filed Jan 18, 2019 22:20 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantStock option (right to buy) · Derivative | 40,000 | $0.00 Strike: $4.72 | $0.00 |
DisclosureSEC source: 0001179022-19-000019 · edgar.xml · derivative · entry 3 Uihlein Richard E · CIK 0001694903 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common stock · 40,000 shares Expires 2029-01-16 F2 · derivative.exercise_date: The options vest 100% on January 16, 2020. Read SEC document |
| January 16, 2019 Filed Jan 18, 2019 22:20 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantCommon Stock | 7,415 | $4.72 | $34,998.80 |
DisclosureSEC source: 0001179022-19-000019 · edgar.xml · nonDerivative · entry 1 Uihlein Richard E · CIK 0001694903 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,535,289 F1 · shares: These restricted shares were issued in lieu of cash retainer and meeting fees of $35,000 for 2019. Restrictions on the shares lapse at a rate of 25% at the end of each calendar quarter in 2019. Read SEC document |
| December 14, 2017 Filed Dec 18, 2017 21:10 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantStock option (right to buy) · Derivative | 46,875 | $0.00 Strike: $2.39 | $0.00 |
DisclosureSEC source: 0001179022-17-000075 · edgar.xml · derivative · entry 3 Uihlein Richard E · CIK 0001694903 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,875 Underlying: Common stock · 46,875 shares Expires 2027-12-14 F3 · derivative.exercise_date: The options vest 100% on December 14, 2018. Read SEC document |
| December 14, 2017 Filed Dec 18, 2017 21:10 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantCommon Stock | 14,644 | $2.39 | $34,999.16 |
DisclosureSEC source: 0001179022-17-000075 · edgar.xml · nonDerivative · entry 1 Uihlein Richard E · CIK 0001694903 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,524,553 F1 · shares: These restricted shares were issued in lieu of cash retainer and meeting fees of $35,000 for 2018. Restrictions on the shares lapse at a rate of 25% per calendar quarter in 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.